ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

Final Issue Of Decade; Office Closed, But Not Phone Or Fax

December 15, 1989

FDA Approves Ribavirin Phase 102 Trials

October 30, 1987

In Brief: Markup Of Cancer Act Renewal Bill Oct. 31; Garfinkel New ACS VP For Epidemiology

October 19, 1979

In Senate testimony, NCI director uses survival rate as measure of progress for goal to “eliminate suffering and death due to cancer.”

July 29, 2005

Drug Cleared For GIST And Kidney Cancer, FDA’s First Two-Indication Cancer Approval

January 27, 2006

FDA Approves NDA For Mylan’s Paclitaxel For Ovarian And Breast Cancer Treatment.

July 27, 2001